Nexus (NXU) Q1 2025 earnings summary

Executive summary

• Sales grew 11.2% year-over-year to KEUR 70,022 in Q1 2025, driven by strong demand for digital healthcare solutions and new project wins across Europe.

• EBITDA increased 23.0% to KEUR 15,934, and EBIT rose 34.5% to KEUR 11,259 compared to Q1 2024.

• Net income climbed 23.1% to KEUR 8,239, with EPS up 26.3% to EUR 0.48.

• Operating cash flow surged 33.9% to KEUR 34,199, and liquidity reached KEUR 144,886.

• Acquisition of HD-Clinical in England contributed KEUR 1,261 in revenue and KEUR -100 in EBITDA; integration costs totaled KEUR 660.

Financial highlights

• Domestic sales rose 18.9% to KEUR 41,573; international sales up 1.6% to KEUR 28,449.

• Segment revenues: NEXUS/DE +27.1%, NEXUS/DIS +25.5%, NEXUS/ROE -0.7% year-over-year.

• Maintenance and recurring income up 15.2%; license sales up 53.9%; service revenue declined 18.3%.

• Investments in tangible and intangible assets totaled KEUR 1,934, including KEUR 1,103 for software development capitalization.

• Share price closed at EUR 70.00 on 31/03/2025, up 24.3% year-over-year; market capitalization EUR 1,214.58 million.

Outlook and guidance

• Management expects continued strong sales and earnings growth, supported by robust order intake and promising tenders.

• Focus remains on project implementation, product development, and leveraging Q1 momentum for full-year targets.

• Ongoing acquisition opportunities are being evaluated to strengthen product and market position.